Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 16/20 | 0.55 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29781083 | 1.00 | NR1H2 (0.55) | NR1H2NR1H3MCL1DAOCA12 | |
| SCHEMBL29524946 | 0.88 | NR1H2 (0.55) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL4251782 | 0.87 | NR1H2 (0.54) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL29725642 | 0.87 | NR1H2 (0.54) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL3852059 | 0.87 | NR1H2 (0.57) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL18537881 | 0.86 | NR1H2 (0.53) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL5957852 | 0.83 | NR1H2 (0.51) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL6988076 | 0.83 | MCL1 (0.58) | MCL1DAOALDH1A1TSHR | |
| SCHEMBL3995157 | 0.83 | NR1H2 (0.42) | NR1H2NR1H3MCL1ALDH1A1 | |
| SCHEMBL24894603 | 0.82 | NOD2 (0.62) | NR1H2NR1H3CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| CN-101541748-A | Methods for treating hepatitis C | PTC THERAPEUTICS INC (US) | 2009-09-23 | — | — | CN | disclosed |
| US-6228868-B1 | ANTICARCINOGENIC AND ANTITUMOR AGENTS | ABBOTT LABORATORIES | 2001-05-08 | — | — | US | disclosed |
| US-RE37094-E1 | Heterocyclic substituted acylaminothiazoles, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 2001-03-13 | — | — | US | disclosed |
| US-5380736-A | Cholecystokinin and gastric antagonist | ELF SANOFI (FR) | 1995-01-10 | — | — | US | disclosed |
| US-5314889-A | Hormone antagonists | ELF SANOFI (FR) | 1994-05-24 | — | — | US | disclosed |
| US-5189049-A | Cholecystokinin and gastrin inhibitors | SANOFI (FR) | 1993-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | NR1H2 247/4885NR1H3 123/4885MCL1 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.